Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

BACKGROUND: Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrarotto, Renata, Anderson, Ian, Medgyasszay, Balazs, García‐Campelo, Maria Rosario, Edenfield, William, Feinstein, Trevor M., Johnson, Jennifer M., Kalmadi, Sujith, Lammers, Philip E., Sanchez‐Hernandez, Alfredo, Pritchett, Yili, Morris, Shannon R., Malik, Rajesh K., Csőszi, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419768/
https://www.ncbi.nlm.nih.gov/pubmed/34405547
http://dx.doi.org/10.1002/cam4.4089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419768/
https://www.ncbi.nlm.nih.gov/pubmed/34405547
http://dx.doi.org/10.1002/cam4.4089

Ejemplares similares